[go: up one dir, main page]

WO2006105798A3 - Benzimidazole formulation - Google Patents

Benzimidazole formulation Download PDF

Info

Publication number
WO2006105798A3
WO2006105798A3 PCT/DK2006/000409 DK2006000409W WO2006105798A3 WO 2006105798 A3 WO2006105798 A3 WO 2006105798A3 DK 2006000409 W DK2006000409 W DK 2006000409W WO 2006105798 A3 WO2006105798 A3 WO 2006105798A3
Authority
WO
WIPO (PCT)
Prior art keywords
dry
manufacturing process
pharmaceutical formulation
benzimidazole
superfluous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/000409
Other languages
French (fr)
Other versions
WO2006105798A2 (en
Inventor
Poul Bertelsen
Peder Mohr Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Priority to EP06753346A priority Critical patent/EP1901719A2/en
Priority to AU2006230974A priority patent/AU2006230974C1/en
Priority to CA002614526A priority patent/CA2614526A1/en
Priority to EA200800290A priority patent/EA015535B1/en
Publication of WO2006105798A2 publication Critical patent/WO2006105798A2/en
Publication of WO2006105798A3 publication Critical patent/WO2006105798A3/en
Anticipated expiration legal-status Critical
Priority to NO20080691A priority patent/NO20080691L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A dry manufacturing process for the production of a pharmaceutical formulation of a benzimidazole and an alkaline substance is described. A tablet is compressed directly from a dry powder or a dry particulate matter avoiding any liquid or excipient conventionally used as a wet binder. The manufacturing process has the advantage of being simple and cost efficient. At the same time an expensive drying step is superfluous. The resulting pharmaceutical formulation has a good stability and a good dissolution profile.
PCT/DK2006/000409 2005-07-11 2006-07-11 Benzimidazole formulation Ceased WO2006105798A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06753346A EP1901719A2 (en) 2005-07-11 2006-07-11 Benzimidazole formulation
AU2006230974A AU2006230974C1 (en) 2005-07-11 2006-07-11 Benzimidazole formulation
CA002614526A CA2614526A1 (en) 2005-07-11 2006-07-11 Benzimidazole formulation
EA200800290A EA015535B1 (en) 2005-07-11 2006-07-11 Benzimidazole formulation
NO20080691A NO20080691L (en) 2005-07-11 2008-02-07 Benzimidazole formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200501019 2005-07-11
DKPA200501019 2005-07-11
US72785505P 2005-10-19 2005-10-19
US60/727,855 2005-10-19

Publications (2)

Publication Number Publication Date
WO2006105798A2 WO2006105798A2 (en) 2006-10-12
WO2006105798A3 true WO2006105798A3 (en) 2006-12-07

Family

ID=37492042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000409 Ceased WO2006105798A2 (en) 2005-07-11 2006-07-11 Benzimidazole formulation

Country Status (5)

Country Link
EP (1) EP1901719A2 (en)
AU (1) AU2006230974C1 (en)
CA (1) CA2614526A1 (en)
EA (1) EA015535B1 (en)
WO (1) WO2006105798A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5228359B2 (en) * 2007-04-12 2013-07-03 ニプロ株式会社 Active ingredient particles, process for producing the same and orally disintegrating tablets
TWI441658B (en) 2008-03-11 2014-06-21 Takeda Pharmaceutical Orally-disintegrating solid preparation
TR201000948A1 (en) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazole formulations.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103479593B (en) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 Preparation method for omeprazole enteric coated tablet
CN103386133A (en) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 Oral instant preparation of proton pump inhibitor and preparation method thereof
PL3524595T3 (en) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
HUE064614T2 (en) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Process for suppressing the bitter taste of a quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104825414B (en) * 2015-05-07 2018-11-16 山东新时代药业有限公司 A kind of stable S-pantoprazole sodium enteric tablet
ES2886107T3 (en) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplastic
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
KR102539920B1 (en) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 Tumor-Treatment Pharmaceutical Composition
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN113318079B (en) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 A method for improving the dissolution of triclabendazole granules and its dissolution detection method
CN115645373B (en) * 2022-12-24 2024-01-30 山东理工职业学院 A kind of preparation method of omeprazole sodium tablets

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
EP1004305A1 (en) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
WO2004075881A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
WO2004112756A1 (en) * 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005009410A2 (en) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Pharmaceutical compositions having a swellable coating

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
AR036354A1 (en) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd SOLID PREPARATION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
EP1004305A1 (en) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
WO2004075881A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
WO2004112756A1 (en) * 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005009410A2 (en) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Pharmaceutical compositions having a swellable coating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1901719A2 *

Also Published As

Publication number Publication date
EA015535B1 (en) 2011-08-30
AU2006230974B2 (en) 2011-09-29
WO2006105798A2 (en) 2006-10-12
CA2614526A1 (en) 2006-10-12
AU2006230974C1 (en) 2012-02-02
EA200800290A1 (en) 2008-08-29
EP1901719A2 (en) 2008-03-26
AU2006230974A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006105798A3 (en) Benzimidazole formulation
NO20035654D0 (en) Dry powder formulation delivery system
IL163642A0 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ITBO20010082A0 (en) TABLET PRESSING MACHINE FOR THE PRODUCTION OF TABLETS
SI1689370T2 (en) METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( š (5-2-oxo-3- Š4- (3-oxo-4-morpholinyl)-phenylĆ-1, 3- oxazolidin-5-ylć-methyl)-2-thiophencarboxamide
NO20014835L (en) Process for the preparation of monodisperse polymer particles
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
WO2005112897A3 (en) Immediate release pharmaceutical tablets with height greater than width
ITBO20010141A0 (en) TABLET PRESSING MACHINE FOR THE PRODUCTION OF TABLETS
IL156803A0 (en) Coated barium titanate-based particles and process for the production thereof
WO2010116223A3 (en) Method for manufacturing a paper container
NO20062795L (en) Process for the preparation of granular chocolate base materials for chocolate production and products thereof
NO20080691L (en) Benzimidazole formulation
NL1013849A1 (en) Method for manufacturing powdered dielectric ceramic starting material.
ZA200810345B (en) Process for preparing spray dried formulations of tmc125
ITBO20040014A1 (en) COMPRESSING MACHINE FOR THE PRODUCTION OF TABLETS
IL200447A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
NO20042022L (en) Solid drug formulation containing pipiperazine urea derivative and process for preparing the formulation
PT1819320E (en) Orally dispersible pharmaceutical composition and process for the preparation thereof
EP2907636A1 (en) Production method for honeycomb structure
EP1840103A3 (en) Production process of sheet-like dense cordierite sintered body
WO2007072497A3 (en) Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
EP1954246A4 (en) Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
PL378157A1 (en) Semi-fluid pharmaceutical compound based on methyl cellulose and method for the obtainment of semi-fluid pharmaceutical compound based on methyl cellulose
UA40999A (en) Method for manufacturing solid form of pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753346

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2614526

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006230974

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2006230974

Country of ref document: AU

Date of ref document: 20060711

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006230974

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200800290

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006753346

Country of ref document: EP